Compare AbCellera Biologics Inc (ABCL) vs Abercrombie & Fitch Co. (ANF) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Abercrombie & Fitch Co. — how do they compare? AbCellera Biologics Inc trades at $7.25 (market cap $2.35B), while Abercrombie & Fitch Co. trades at $86.37 (market cap $3.96B). The key difference: Abercrombie & Fitch Co. is the larger of the two by market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Abercrombie & Fitch Co. nearer its low. Which is the better fit depends on your goals.
| ABCL | ANF | |
|---|---|---|
Market Cap | $2.35B | $3.96B |
Sector | Health | Consumer Cyclical |
52-Week High | $8.12 | $129.85 |
52-Week Low | $2.78 | $65.61 |
Enterprise Value | $1.99B | $4.63B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
ANF trades at $89.07, down 3.61% today but maintains strong fundamentals with a P/E of 8.68 and robust profitability metrics including 39.04% ROE. The stock shows technical bullish signals with support at $88 and resistance at $92. Recent earnings beats and 2025 revenue growth to $4.95B demonstrate operational strength, while expansion into third-party footwear and Target partnerships highlight growth initiatives.
ANF presents a compelling value opportunity with attractive valuation multiples and consistent earnings outperformance. Key risks include moderating sales growth and international market softness. Analyst consensus price target of $107.71 suggests 21% upside potential, supported by strong institutional sentiment despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Abercrombie & Fitch Co.
Abercrombie & Fitch Co is a specialty retailer that sells casual clothing, personal-care products, and accessories for men, women, and children. It sells direct to consumer through its stores and websites, which include the Abercrombie & Fitch, Abercrombie kids, and Hollister brands. Most stores are in the United States, but the company does have many stores in Canada, Europe, and Asia. All stores are leased. Abercrombie ships to well over 100 countries via its websites. The company sources its merchandise from dozens of vendors that are primarily located in Asia and Central America. Abercrombie has two distribution centers in Ohio to support its North American operations. It uses third-party distributors for sales in Europe and Asia.
Read more on ANF →
